Protocol Ledger

NCT02606045 · Phase III · TERMINATED

Minimize Menorrhagia in Women With Von Willebrand Disease

Interventional Phase III clinical trial protocol NCT02606045 sponsored by Margaret Ragni in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-02-07 Enrollment: 39 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT02606045
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)39 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT02606045
Protocol FieldVerified Registry Value
NCT IdentifierNCT02606045
Consolidated Lead SponsorMargaret Ragni
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment39 participants (ACTUAL)
Registered Start Date2019-02-07
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI